Author

Wen Jess Li

Roswell Park Comprehensive Cancer CenterORCID 0000-0001-6906-1256Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Research Focus:clustering· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Dean G. TangiD· 3 shared Xiaozhuo LiuiD· 3 shared Anmbreen JamrozeiD· 2 shared Gurkamal S. ChattaiD· 2 shared Han Yu· 2 shared Igor J. PuzanoviD· 2 shared Jason S. KirkiD· 2 shared Kent L. NastiukiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Dean G. TangORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival

Xiaozhuo Liu, Anmbreen Jamroze, Eduardo Cortes, Yibing Ji, Kathy Zhao, Faming Zhao, Julian Ho, Yang Seagle Liu, Elai Davicioni, Shan Wu, Wen Jess Li, Felix Yi-Chung Feng, Joshi J. Alumkal, Daniel Eidelberg Spratt, Christopher J. Sweeney, , Dean G. Tang

This study quantifies cancer stemness in prostate cancer across progression stages, showing its association with therapy resistance, poor survival, and lineage plasticity.

Molecular Cancer · Oct 27, 2026Peer-reviewedCancer Biology

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study validate BCL-2 as a target across heterogeneous CRPC subtypes

Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou, Wen Jess Li, Han Yu, Amanda Tracz, Justine J. Jacobi, Qiuhui Li, Kent L. Nastiuk, Xin Chen, Jiaoti Huang, Kevin Lin, Mingyu Liu, Changmeng Cai, Yue Lu, , Dean G. Tang

This study validates BCL-2 as a therapeutic target in CRPC by showing its upregulation under AR inhibition and demonstrating efficacy of BCL-2 inhibitors in preclinical and clinical models.

Signal Transduction and Targeted Therapy · May 1, 2026Peer-reviewedCancer Biology

Loss of ATG5 expression in a subset of human prostate cancers promotes tumor growth through accumulation of p62

Daric J. Wible, Wen Jess Li, Xiaozhuo Liu, Manu M. Sebastian, Dean G. Tang, Shawn B. Bratton

The paper shows that loss of ATG5 in prostate cancers leads to tumor growth by accumulating p62, suggesting ATG5 acts as a tumor suppressor in this context.

bioRxiv · May 2, 2025 · PreprintCancer Biology